Mirabegron elicits rat corpus cavernosum relaxation and increases in vivo erectile response

Detalhes bibliográficos
Autor(a) principal: de Oliveira, Mariana G.
Data de Publicação: 2019
Outros Autores: Rojas-Moscoso, Julio Alejandro, Bertollotto, Gabriela M., Candido, Tuany Z., Kiguti, Luiz Ricardo de A., Pupo, André S. [UNESP], Antunes, Edson, De Nucci, Gilberto, Mónica, Fabíola Z.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UNESP
Texto Completo: http://dx.doi.org/10.1016/j.ejphar.2019.172447
http://hdl.handle.net/11449/187789
Resumo: Mirabegron is the first β3-adrenoceptor agonist approved on the market and may offer beneficial pharmacological action in patients with overactive bladder and erectile dysfunction. Here, we further investigate the mechanisms by which mirabegron induces rat corpus cavernosum (CC) relaxation. Adult male Wistar rats were used. The CC were isolated for in vitro functional assays and β-adrenoceptors subtypes mRNA expression evaluation. Animals were treated orally with mirabegron (30 mg/kg, 3 h), tadalafil (10 mg/kg, 3 h) or both for intracavernous pressure (ICP). Intracellular levels of cAMP and cGMP were also determined. The β1-, β2- and β3-adrenoceptors subtypes were expressed in rat CC. Mirabegron produced concentration-dependent CC relaxations that were unaffected by the β1-, β2- or β3-adrenoceptor antagonists atenolol (1 μM), ICI-118,551 (1 μM) and L748,337 (10 μM), respectively. Mirabegron-induced relaxations were not affected by the phosphodiesterase type 4 inhibitor, rolipram, or the adenylyl cyclase selective inhibitor, SQ 22,536. Potassium channel- or calcium influx-blockade are not involved in mirabegron-induced relaxations. In contrast, mirabegron produced rightward shifts in the contractile response induced by the α1-adrenoceptor agonist, phenylephrine. Finally, cavernous nerve stimulation caused frequency-dependent ICP increases, which were significantly increased in rats treated with mirabegron in a similar degree of tadalafil-treated rat, without promoting a significant cAMP or cGMP accumulation. Together, our results demonstrate that mirabegron induced CC relaxation through α1-adrenoceptor blockade. Care should be taken to translate the effect of mirabegron into the clinic, especially when using rat as an animal model of erectile dysfunction.
id UNSP_d6a21309a9eaa227f2b0cf9d9907bf1d
oai_identifier_str oai:repositorio.unesp.br:11449/187789
network_acronym_str UNSP
network_name_str Repositório Institucional da UNESP
repository_id_str 2946
spelling Mirabegron elicits rat corpus cavernosum relaxation and increases in vivo erectile responseCyclic AMPCyclic GMPErectile dysfunctionIntracavernous pressureMirabegronTadalafilMirabegron is the first β3-adrenoceptor agonist approved on the market and may offer beneficial pharmacological action in patients with overactive bladder and erectile dysfunction. Here, we further investigate the mechanisms by which mirabegron induces rat corpus cavernosum (CC) relaxation. Adult male Wistar rats were used. The CC were isolated for in vitro functional assays and β-adrenoceptors subtypes mRNA expression evaluation. Animals were treated orally with mirabegron (30 mg/kg, 3 h), tadalafil (10 mg/kg, 3 h) or both for intracavernous pressure (ICP). Intracellular levels of cAMP and cGMP were also determined. The β1-, β2- and β3-adrenoceptors subtypes were expressed in rat CC. Mirabegron produced concentration-dependent CC relaxations that were unaffected by the β1-, β2- or β3-adrenoceptor antagonists atenolol (1 μM), ICI-118,551 (1 μM) and L748,337 (10 μM), respectively. Mirabegron-induced relaxations were not affected by the phosphodiesterase type 4 inhibitor, rolipram, or the adenylyl cyclase selective inhibitor, SQ 22,536. Potassium channel- or calcium influx-blockade are not involved in mirabegron-induced relaxations. In contrast, mirabegron produced rightward shifts in the contractile response induced by the α1-adrenoceptor agonist, phenylephrine. Finally, cavernous nerve stimulation caused frequency-dependent ICP increases, which were significantly increased in rats treated with mirabegron in a similar degree of tadalafil-treated rat, without promoting a significant cAMP or cGMP accumulation. Together, our results demonstrate that mirabegron induced CC relaxation through α1-adrenoceptor blockade. Care should be taken to translate the effect of mirabegron into the clinic, especially when using rat as an animal model of erectile dysfunction.Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)Department of Pharmacology Faculty of Medical Sciences University of Campinas (UNICAMP)Department of Pharmacology Institute of Biosciences São Paulo State University (UNESP)Department of Pharmacology Institute of Biosciences São Paulo State University (UNESP)FAPESP: 2013/13907–4FAPESP: 2017/15175–1FAPESP: 2018/09765–3Universidade Estadual de Campinas (UNICAMP)Universidade Estadual Paulista (Unesp)de Oliveira, Mariana G.Rojas-Moscoso, Julio AlejandroBertollotto, Gabriela M.Candido, Tuany Z.Kiguti, Luiz Ricardo de A.Pupo, André S. [UNESP]Antunes, EdsonDe Nucci, GilbertoMónica, Fabíola Z.2019-10-06T15:47:16Z2019-10-06T15:47:16Z2019-09-05info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlehttp://dx.doi.org/10.1016/j.ejphar.2019.172447European Journal of Pharmacology, v. 858.1879-07120014-2999http://hdl.handle.net/11449/18778910.1016/j.ejphar.2019.1724472-s2.0-85067626097Scopusreponame:Repositório Institucional da UNESPinstname:Universidade Estadual Paulista (UNESP)instacron:UNESPengEuropean Journal of Pharmacologyinfo:eu-repo/semantics/openAccess2021-10-22T21:10:07Zoai:repositorio.unesp.br:11449/187789Repositório InstitucionalPUBhttp://repositorio.unesp.br/oai/requestopendoar:29462024-08-05T19:13:32.942789Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)false
dc.title.none.fl_str_mv Mirabegron elicits rat corpus cavernosum relaxation and increases in vivo erectile response
title Mirabegron elicits rat corpus cavernosum relaxation and increases in vivo erectile response
spellingShingle Mirabegron elicits rat corpus cavernosum relaxation and increases in vivo erectile response
de Oliveira, Mariana G.
Cyclic AMP
Cyclic GMP
Erectile dysfunction
Intracavernous pressure
Mirabegron
Tadalafil
title_short Mirabegron elicits rat corpus cavernosum relaxation and increases in vivo erectile response
title_full Mirabegron elicits rat corpus cavernosum relaxation and increases in vivo erectile response
title_fullStr Mirabegron elicits rat corpus cavernosum relaxation and increases in vivo erectile response
title_full_unstemmed Mirabegron elicits rat corpus cavernosum relaxation and increases in vivo erectile response
title_sort Mirabegron elicits rat corpus cavernosum relaxation and increases in vivo erectile response
author de Oliveira, Mariana G.
author_facet de Oliveira, Mariana G.
Rojas-Moscoso, Julio Alejandro
Bertollotto, Gabriela M.
Candido, Tuany Z.
Kiguti, Luiz Ricardo de A.
Pupo, André S. [UNESP]
Antunes, Edson
De Nucci, Gilberto
Mónica, Fabíola Z.
author_role author
author2 Rojas-Moscoso, Julio Alejandro
Bertollotto, Gabriela M.
Candido, Tuany Z.
Kiguti, Luiz Ricardo de A.
Pupo, André S. [UNESP]
Antunes, Edson
De Nucci, Gilberto
Mónica, Fabíola Z.
author2_role author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Universidade Estadual de Campinas (UNICAMP)
Universidade Estadual Paulista (Unesp)
dc.contributor.author.fl_str_mv de Oliveira, Mariana G.
Rojas-Moscoso, Julio Alejandro
Bertollotto, Gabriela M.
Candido, Tuany Z.
Kiguti, Luiz Ricardo de A.
Pupo, André S. [UNESP]
Antunes, Edson
De Nucci, Gilberto
Mónica, Fabíola Z.
dc.subject.por.fl_str_mv Cyclic AMP
Cyclic GMP
Erectile dysfunction
Intracavernous pressure
Mirabegron
Tadalafil
topic Cyclic AMP
Cyclic GMP
Erectile dysfunction
Intracavernous pressure
Mirabegron
Tadalafil
description Mirabegron is the first β3-adrenoceptor agonist approved on the market and may offer beneficial pharmacological action in patients with overactive bladder and erectile dysfunction. Here, we further investigate the mechanisms by which mirabegron induces rat corpus cavernosum (CC) relaxation. Adult male Wistar rats were used. The CC were isolated for in vitro functional assays and β-adrenoceptors subtypes mRNA expression evaluation. Animals were treated orally with mirabegron (30 mg/kg, 3 h), tadalafil (10 mg/kg, 3 h) or both for intracavernous pressure (ICP). Intracellular levels of cAMP and cGMP were also determined. The β1-, β2- and β3-adrenoceptors subtypes were expressed in rat CC. Mirabegron produced concentration-dependent CC relaxations that were unaffected by the β1-, β2- or β3-adrenoceptor antagonists atenolol (1 μM), ICI-118,551 (1 μM) and L748,337 (10 μM), respectively. Mirabegron-induced relaxations were not affected by the phosphodiesterase type 4 inhibitor, rolipram, or the adenylyl cyclase selective inhibitor, SQ 22,536. Potassium channel- or calcium influx-blockade are not involved in mirabegron-induced relaxations. In contrast, mirabegron produced rightward shifts in the contractile response induced by the α1-adrenoceptor agonist, phenylephrine. Finally, cavernous nerve stimulation caused frequency-dependent ICP increases, which were significantly increased in rats treated with mirabegron in a similar degree of tadalafil-treated rat, without promoting a significant cAMP or cGMP accumulation. Together, our results demonstrate that mirabegron induced CC relaxation through α1-adrenoceptor blockade. Care should be taken to translate the effect of mirabegron into the clinic, especially when using rat as an animal model of erectile dysfunction.
publishDate 2019
dc.date.none.fl_str_mv 2019-10-06T15:47:16Z
2019-10-06T15:47:16Z
2019-09-05
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://dx.doi.org/10.1016/j.ejphar.2019.172447
European Journal of Pharmacology, v. 858.
1879-0712
0014-2999
http://hdl.handle.net/11449/187789
10.1016/j.ejphar.2019.172447
2-s2.0-85067626097
url http://dx.doi.org/10.1016/j.ejphar.2019.172447
http://hdl.handle.net/11449/187789
identifier_str_mv European Journal of Pharmacology, v. 858.
1879-0712
0014-2999
10.1016/j.ejphar.2019.172447
2-s2.0-85067626097
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv European Journal of Pharmacology
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.source.none.fl_str_mv Scopus
reponame:Repositório Institucional da UNESP
instname:Universidade Estadual Paulista (UNESP)
instacron:UNESP
instname_str Universidade Estadual Paulista (UNESP)
instacron_str UNESP
institution UNESP
reponame_str Repositório Institucional da UNESP
collection Repositório Institucional da UNESP
repository.name.fl_str_mv Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)
repository.mail.fl_str_mv
_version_ 1808129036567707648